Stockreport

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials [Yahoo! Finance]

LENZ Therapeutics, Inc.  (LENZ) 
PDF – Rapid onset and long duration shown with 71% of participants achieving three-lines or greater improvement at 30 minutes and 40% at 10 hours – New Drug Application s [Read more]